Human colorectal CD24+ cancer stem cells are susceptible to epithelial-mesenchymal transition
Author(s) -
Miho Okano,
Masamitsu Konno,
Yoshihiro Kano,
Hirotoshi Kim,
Koichi Kawamoto,
Masahisa Ohkuma,
Naotsugu Haraguchi,
Takehiko Yokobori,
Koshi Mimori,
Hirofumi Yamamoto,
Mitsugu Sekimoto,
Yuichiro� Doki,
Masaki Mori,
Hideshi Ishii
Publication year - 2014
Publication title -
international journal of oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.405
H-Index - 122
ISSN - 1019-6439
DOI - 10.3892/ijo.2014.2462
Subject(s) - cd24 , cancer stem cell , epithelial–mesenchymal transition , cancer research , metastasis , biology , cancer , colorectal cancer , cancer cell , oncogene , stem cell , immunology , cell cycle , microbiology and biotechnology , genetics
Conventional cancer chemotherapy preferentially destroys non-stem cancer cells within a tumor, and a subpopulation of cancer stem cells (CSCs) is more resistant and survives, leading to relapses and metastasis. Howeve, recent studies suggest that CD24 and susceptibility to epithelial-mesenchymal transition (EMT) can serve as markers of CSCs. We report that CD24(+) cells are susceptible to induction of EMT, a phenotype important for cancer metastasis. We studied the responsiveness of CSC markers to TGF-β , an effective EMT inducer. The data on CD24 demonstrated that CD24(+) cells are susceptible to EMT, a phenotype important for cancer metastasis in two colorectal cancer cell lines, the CaR-1 and CCK81. CD24(+) cells expressed Notch 1 in response to exposure to TGF-β in culture and showed higher tumorigenic activity compared to controls. This evidence shows that CD24(+) cells are susceptible to EMT induction and to cancer progression and is indicative of the candidacy of CD24 as a therapeutic target in CSC.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom